NexgenRx Inc.
NEGXF
$0.1964
$0.00492.56%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.93M | 3.02M | 2.72M | 2.94M | 2.81M |
| Total Other Revenue | 214.70K | 146.90K | 97.10K | 105.10K | 110.60K |
| Total Revenue | 3.14M | 3.17M | 2.81M | 3.05M | 2.92M |
| Cost of Revenue | 567.70K | 645.70K | 405.20K | 727.60K | 596.80K |
| Gross Profit | 2.57M | 2.53M | 2.41M | 2.32M | 2.32M |
| SG&A Expenses | 2.10M | 1.92M | 1.85M | 1.97M | 2.03M |
| Depreciation & Amortization | 233.40K | 218.80K | 225.60K | 227.10K | 235.50K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.90M | 2.79M | 2.48M | 2.93M | 2.86M |
| Operating Income | 245.00K | 383.10K | 332.50K | 123.00K | 61.80K |
| Income Before Tax | 239.00K | 351.40K | 323.70K | 92.70K | 6.60K |
| Income Tax Expenses | -16.50K | -15.90K | 343.40K | -16.80K | -16.70K |
| Earnings from Continuing Operations | 255.50K | 367.30K | -19.70K | 109.40K | 23.30K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 255.50K | 367.30K | -19.70K | 109.40K | 23.30K |
| EBIT | 245.00K | 383.10K | 332.50K | 123.00K | 61.80K |
| EBITDA | 478.40K | 580.10K | 369.70K | 350.10K | 297.30K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 71.12M | 71.12M | 70.47M | 71.08M | 70.92M |
| Average Diluted Shares Outstanding | 76.92M | 76.72M | 70.47M | 76.68M | 76.92M |
| Dividend Per Share | 0.00 | -- | 0.00 | 0.00 | 0.00 |
| Payout Ratio | 109.92% | 6.26% | -370.20% | 22.11% | 1,214.16% |